|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang T, Wu MH, Wu YM and Zhang WY: A
population-based study of invasive cervical cancer patients in
Beijing: 1993–2008. Chin Med J (Engl). 128:3298–3304. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Angioli R, Plotti F, Luvero D, Aloisi A,
Guzzo F, Capriglione S, Terranova C, De Cicco Nardone C and
Benedetti-Panici P: Feasibility and safety of carboplatin plus
paclitaxel as neoadjuvant chemotherapy for locally advanced
cervical cancer: A pilot study. Tumour Biol. 35:2741–2746. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Organista-Nava J, Gómez-Gómez Y and
Gariglio P: Embryonic stem cell-specific signature in cervical
cancer. Tumour Biol. 35:1727–1738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Du PL, Wu KS, Fang JY, Zeng Y, Xu ZX, Tang
WR, Xu XL and Lin K: Cervical cancer mortality trends in China,
1991–2013, and predictions for the future. Asian Pac J Cancer Prev.
16:6391–6396. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wentzensen N, Schwartz L, Zuna RE, Smith
K, Mathews C, Gold MA, Allen RA, Zhang R, Dunn ST, Walker JL and
Schiffman M: Performance of p16/Ki-67 immunostaining to detect
cervical cancer precursors in a colposcopy referral population.
Clin Cancer Res. 18:4154–4162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schwarz JK, Payton JE, Rashmi R, Xiang T,
Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS and
Grigsby PW: Pathway-specific analysis of gene expression data
identifies the PI3K/Akt pathway as a novel therapeutic target in
cervical cancer. Clin Cancer Res. 18:1464–1471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rhodes J, York RD, Tara D, Tajinda K and
Druker BJ: CrkL functions as a nuclear adaptor and transcriptional
activator in Bcr-Abl-expressing cells. Exp Hematol. 28:305–310.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feller SM: Crk family adaptors-signalling
complex formation and biological roles. Oncogene. 20:6348–6371.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fidler IJ and Kripke ML: Genomic analysis
of primary tumors does not address the prevalence of metastatic
cells in the population. Nat Genet. 34(23): author reply 25.
2003.PubMed/NCBI
|
|
11
|
ten Hoeve J, Morris C, Heisterkamp N and
Groffen J: Isolation and chromosomal localization of CRKL, a human
crk-like gene. Oncogene. 8:2469–2474. 1993.PubMed/NCBI
|
|
12
|
Sattler M, Salgia R, Shrikhande G, Verma
S, Pisick E, Prasad KV and Griffin JD: Steel factor induces
tyrosine phosphorylation of CRKL and binding of CRKL to a complex
containing c-kit, phosphatidylinositol 3-kinase, and p120 (CBL). J
Biol Chem. 272:10248–10253. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oda T, Heaney C, Hagopian JR, Okuda K,
Griffin JD and Druker BJ: Crkl is the major tyrosine-phosphorylated
protein in neutrophils from patients with chronic myelogenous
leukemia. J Biol Chem. 269:22925–22928. 1994.PubMed/NCBI
|
|
14
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Senechal K, Halpern J and Sawyers CL: The
CRKL adaptor protein transforms fibroblasts and functions in
transformation by the BCR-ABL oncogene. J Biol Chem.
271:23255–23261. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van 't Veer LJ, Dai H, van de Vijver MJ,
He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin F, Chengyao X, Qingchang L, Qianze D,
Enhua W and Yan W: CRKL promotes lung cancer cell invasion through
ERK-MMP9 pathway. Mol Carcinog. 54(Suppl 1): E35–E44. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Dong QZ, Fu L, Stoecker M, Wang E
and Wang EH: Overexpression of CRKL correlates with poor prognosis
and cell proliferation in non-small cell lung cancer. Mol Carcinog.
52:890–899. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Senechal K, Heaney C, Druker B and Sawyers
CL: Structural requirements for function of the Crkl adapter
protein in fibroblasts and hematopoietic cells. Mol Cell Biol.
18:5082–5090. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schönherr C, Yang HL, Vigny M, Palmer RH
and Hallberg B: Anaplastic lymphoma kinase activates the small
GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and
PC12 cells. Oncogene. 29:2817–2830. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao T, Miao Z, Wang Z, Xu Y, Wu J, Liu X,
You Y and Li J: Overexpression of CRKL correlates with malignant
cell proliferation in breast cancer. Tumour Biol. 34:2891–2897.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao S, Li H, Wang Q, Su C, Wang G, Song
H, Zhao L, Luan Z and Su R: The role of c-Src in the invasion and
metastasis of hepatocellular carcinoma cells induced by association
of cell surface GRP78 with activated α2M. BMC Cancer. 15:3892015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tamura M, Sasaki Y, Kobashi K, Takeda K,
Nakagaki T, Idogawa M and Tokino T: CRKL oncogene is downregulated
by p53 through miR-200s. Cancer Sci. 106:1033–1040. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ladanyi M: CRKL as a lung cancer oncogene
and mediator of acquired resistance to EGFR inhibitors: Is it all
that it is cracked up to be? Cancer Discov. 1:560–561. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koval AP, Karas M, Zick Y and LeRoith D:
Interplay of the proto-oncogene proteins CrkL and CrkII in
insulin-like growth factor-I receptor-mediated signal transduction.
J Biol Chem. 273:14780–14787. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu L, Dong Q, Xie C, Wang Y and Li Q: CRKL
protein overexpression enhances cell proliferation and invasion in
pancreatic cancer. Tumour Biol. 36:1015–1022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Singer CF, Hudelist G, Lamm W, Mueller R,
Handl C, Kubista E and Czerwenka K: Active (p)CrkL is overexpressed
in human malignancies: Potential role as a surrogate parameter for
therapeutic tyrosine kinase inhibition. Oncol Rep. 15:353–359.
2006.PubMed/NCBI
|
|
29
|
Kim YH, Kwei KA, Girard L, Salari K, Kao
J, Pacyna-Gengelbach M, Wang P, Hernandez-Boussard T, Gazdar AF,
Petersen I, et al: Genomic and functional analysis identifies CRKL
as an oncogene amplified in lung cancer. Oncogene. 29:1421–1430.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fathers KE, Bell ES, Rajadurai CV, Cory S,
Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, et
al: Crk adaptor proteins act as key signaling integrators for
breast tumorigenesis. Breast Cancer Res. 14:R742012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Graf R, Barbero S, Keller N, Chen L, Uryu
S, Schlaepfer D and Stupack D: Src-inducible association of CrkL
with procaspase-8 promotes cell migration. Cell Adh Migr.
7:362–369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shen Q, Rahn JJ, Zhang J, Gunasekera N,
Sun X, Shaw AR, Hendzel MJ, Hoffman P, Bernier A and Hugh JC: MUC1
initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal
protrusive motility after ligating intercellular adhesion
molecule-1. Mol Cancer Res. 6:555–567. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guarino M: Src signaling in cancer
invasion. J Cell Physiol. 223:14–26. 2010.PubMed/NCBI
|
|
34
|
Cui A, Hua H, Shao T, Song P, Kong Q, Luo
T and Jiang Y: Aflatoxin B1 induces Src phosphorylation and
stimulates lung cancer cell migration. Tumour Biol. 36:6507–6513.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun B, Yang N, Jiang Y, Zhang H, Hou C, Ji
C, Liu Y and Zuo P: Antagomir-1290 suppresses CD133+
cells in non-small cell lung cancer by targeting fyn-related Src
family tyrosine kinase. Tumour Biol. 36:6223–6230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang JH, Nao JF, Zhang M and He P: 20
(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer
HO-8910 cells through PI3K/Akt and XIAP pathways. Tumour Biol.
35:11985–11994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ye G, Lu Q, Zhao W, Du D, Jin L and Liu Y:
Fucoxanthin induces apoptosis in human cervical cancer cell line
HeLa via PI3K/Akt pathway. Tumour Biol. 35:11261–11267. 2014.
View Article : Google Scholar : PubMed/NCBI
|
